Amlodipine Mylan

Quick links

Choose a section

Quick links to important sections

Advertisements

Amlodipine Mylan

Advertisements
Advertisements

Overview of Amlodipine Mylan

Quick Facts

Property Description
Active ingredient Amlodipine (as besilate salt)
Form Tablet (Oral medication)
Pharmacological class Calcium-channel blocker (Dihydropyridine)
Common purpose Antihypertensive and antianginal
Origin Synthetic compound

What Type of Medicine is Amlodipine Mylan?

Amlodipine Mylan is a prescription-only synthetic compound and a single-ingredient product featuring Amlodipine as its active ingredient, which is typically presented as the salt Amlodipine besilate. This specific formulation is manufactured for oral administration and is supplied in the solid tablet dosage form. The medicine is formally classified as a Calcium-channel blocker (CCB) and belongs to the Dihydropyridine subclass, a categorization that is clinically recognized. This pharmacological identity distinguishes it from other classes of antihypertensive agents, confirming its role in routine, consistent maintenance therapy for adult patient groups. Amlodipine is distinguished by its selectivity for vascular smooth muscle cells, indicating a targeted mechanism of action to ease strain on the circulatory system.

The General Purpose of Amlodipine’s Action

The main purpose of this therapeutic agent is to act as an effective antihypertensive and antianginal agent by targeting the process of vascular contraction. Amlodipine achieves its effect by inducing vasodilation through the inhibition of calcium ion influx into the muscle cells of the peripheral arteries. This peripheral arterial relaxation results in a significant reduction of the force opposing blood flow, known as systemic vascular resistance, thereby helping to lower high blood pressure (hypertension). Furthermore, this vasodilation mechanism also benefits the heart muscle by improving oxygen supply to the myocardium, a key factor in managing discomfort associated with angina pectoris.

Advertisements

What side effects are possible with Amlodipine Mylan?

Possible Side Effects and Safety Information

The safety profile for Amlodipine, as documented in official government regulatory information, outlines possible adverse reactions across various physiological systems and defines specific constraints on its use.

Official Adverse Reaction Frequencies

Adverse reactions are officially classified based on their documented frequency in clinical use:

  • Very Common (Affecting ge 1 in 10 patients): The most frequently reported adverse event is edema, particularly swelling of the ankles or feet (peripheral edema).
  • Common (Affecting ge 1 in 100 to < 1 in 10 patients): Frequently reported effects include headache, dizziness, somnolence (sleepiness), palpitations (awareness of heartbeat), flushing, nausea, abdominal pain, and fatigue.

System-Organ Classes and Serious Reactions

Side effects are grouped by the affected organ system, known as System-Organ Classes. These include Vascular disorders (edema, flushing), Nervous system disorders (headache, somnolence), Gastrointestinal disorders (gingival hyperplasia, vomiting), and Cardiac disorders (palpitations, arrhythmia).

Serious adverse reactions documented in regulatory sources, although very rare (affecting fewer than 1 in 10,000 patients), include myocardial infarction (heart attack), severe allergic reactions like angioedema, and severe skin reactions such as Stevens-Johnson Syndrome.

Population and Contextual Safety Notes

The official labeling defines specific safety considerations for certain patient groups. Older adults and patients with hepatic impairment (liver problems) may experience reduced clearance of Amlodipine, leading to increased exposure and requiring caution. The label notes that peripheral swelling is often dose-related, and effects like dizziness and somnolence may be more common at the start of treatment.

Regulatory restrictions formally prohibit the use of Amlodipine in patients with known hypersensitivity to the medicine or related derivatives, and caution is required in conditions such as severe aortic stenosis.

Advertisements

Overdose and Emergency Response

The regulatory information for Amlodipine Mylan overdose focuses on the potential for severe cardiovascular effects and the mandatory requirement to seek immediate medical help, as documented by official health authorities.

Documented Overdose Manifestations

Domain Description
Primary Effects Overdose is characterized by profound and prolonged systemic hypotension (severely low blood pressure) and excessive peripheral vasodilation. This may lead to tachycardia (rapid heart rate) or, in some cases, bradycardia (slow heart rate).
Systemic Risk The resultant lack of adequate blood flow can cause secondary effects like syncope (fainting), dizziness, and light-headedness. Severe exposure may lead to circulatory shock.
Population Notes Increased sensitivity and risk of prolonged effects are noted for geriatric patients and those with hepatic impairment (liver dysfunction).

When to Seek Urgent Medical Help

Any suspected overdose scenario necessitates seeking emergency medical attention immediately. This is required due to the potential for the condition to escalate to life-threatening outcomes, such as shock or myocardial infarction. Immediate action, such as contacting the Poison Help line, is specifically required in this context.

Management Considerations: No specific antidote is known for Amlodipine overdose, necessitating that management be solely symptomatic and supportive treatment. This often involves interventions such as intravenous fluids and vasopressors to manage refractory hypotension. Extended hospital monitoring is often required due to the drug's long half-life.

Advertisements

Therapeutic Uses of Amlodipine Mylan

What Amlodipine Mylan Treats: Main Uses and Benefits

Amlodipine Mylan is commonly used to manage chronic cardiovascular conditions by addressing symptoms related to systemic imbalance (circulatory strain) and symptoms associated with acute or episodic changes (heart discomfort). It may offer support for long-term health. The primary therapeutic domains it is applied in addressing include essential hypertension (high blood pressure), chronic stable angina, and vasospastic angina. It is also relevant for patients with documented coronary artery disease (CAD) to assist with reducing certain cardiovascular risks.

“This medicine may be part of symptomatic management in patients with chronic conditions, contributing to maintaining functional stability.”

The medication primarily helps manage the symptom clusters of sustained high pressure and recurrent chest discomfort. This supports the reduction in the long-term risk of major cardiovascular events like heart attack and stroke. It helps maintain a sense of stability when symptoms are more noticeable, including adult patients and children who experience hypertension.


Quick Fact: Relief for Sustained Circulatory Strain
Primary Use Management of chronic hypertension and angina.
Symptom Focus Addressing symptoms related to heightened physiological activity (circulatory strain).
Benefit Plays a role in managing conditions where functional stability becomes affected.
Context Long-term maintenance therapy for chronic conditions.
Advertisements

Eligibility and Restrictions for Use

Amlodipine Mylan's eligibility is determined by specific regulatory criteria, which define patient groups for whom use is authorized, restricted, or strictly prohibited.

Populations for Whom Use is Contraindicated

Use of Amlodipine Mylan is formally contraindicated in patients with a known hypersensitivity to amlodipine or to other dihydropyridine derivatives. It is also prohibited in the presence of specific acute cardiovascular states, including severe hypotension, shock (including cardiogenic shock), high-grade aortic stenosis (obstruction of the left ventricular outflow tract), and haemodynamically unstable heart failure after acute myocardial infarction.

Age-Related and Conditional Eligibility

Population Group Eligibility Status (Regulatory Wording)
Adults (18+ years) Established use for labeled indications.
Pediatric patients (6–17 years) Established use for hypertension only.
Children under 6 years Safety and effectiveness have not been established.
Hepatic Impairment Use with caution; a lower starting dosage may be considered, particularly in severe cases.
Pregnancy Use only if the potential benefit justifies the potential risk.
Lactation Restricted use; the decision often involves discontinuing nursing.
Renal Impairment No dosage adjustment is typically required.

Eligibility Summary

Official regulatory documents classify patient eligibility based on absolute contraindications and conditional limitations. Groups with established safety profiles, such as adults and pediatric patients aged 6 to 17 for hypertension, are authorized users. However, use is restricted or requires caution for small, fragile, or elderly patients, and those with hepatic impairment or specific forms of heart failure. These classifications strictly govern the authorized population boundaries for the drug's administration.

Advertisements

What should I know about interactions with other medicines?

Amlodipine Mylan Interactions with other medicines and products

Amlodipine Mylan’s interaction profile is primarily defined by its relationship with the CYP3A4 enzyme system and specific co-administration constraints documented in regulatory labeling.

  • Metabolic-Based Exposure Changes: Amlodipine is metabolized by CYP3A4. Co-administration with strong or moderate CYP3A4 inhibitors (such as the antifungal Itraconazole or the antibiotic Clarithromycin) significantly increases Amlodipine exposure. Conversely, strong CYP3A4 inducers (like Rifampicin or the herbal product St. John's Wort) may cause Amlodipine plasma concentrations to decrease or vary.

  • Co-administered Drug Restrictions: Regulatory documentation specifies that the daily dose of Simvastatin must be limited to a maximum of 20 mg because Amlodipine is documented to increase the exposure of Simvastatin. Amlodipine may also increase the blood levels of immunosuppressants, including Tacrolimus and Cyclosporine, necessitating patient monitoring.

  • Specific Prohibitions and Substances: Co-administration with Dantrolene infusion must be avoided due to the specific risk of hyperkalemia and cardiovascular compromise. Furthermore, Grapefruit or Grapefruit juice is not recommended as it can increase Amlodipine bioavailability. Concomitant use with alcohol may cause additive hypotensive effects.

  • Population Considerations: The clinical effects of interactions caused by CYP3A4 inhibitors may be more pronounced in elderly patients. Effects may also be increased in patients with hepatic impairment due to reduced clearance.

Advertisements

Mechanism of Action

Molecular Mechanism of Amlodipine

Amlodipine functions by selectively blocking the L-type Voltage-Dependent Calcium Channels ( L-VDCCs), which are protein structures controlling the entry of extracellular calcium ions ( Ca^2+) into vascular smooth muscle cells. The drug interacts specifically at the dihydropyridine binding site, inhibiting the calcium influx required for muscle contraction. This blockade is voltage-dependent, meaning the inhibitory effect is more pronounced on constantly active, depolarized arteries.

This reduction in intracellular Ca^2+ concentration limits the activation of contractile proteins, leading to the relaxation, or vasodilation, of the arterial walls. This action is concentrated on the peripheral resistance arteries, resulting in a reduction in the overall resistance against blood flow, known as Systemic Vascular Resistance (SVR), which reduces the demand placed on the heart's pumping function.

Furthermore, the same mechanism of vasodilation is exerted on the coronary arteries, leading to an increase in the flow of oxygenated blood to the myocardium (heart muscle), modifying the relationship between oxygen needs and supply. The drug's peripheral selectivity limits its direct effect on heart rate or contractility.

Advertisements

Dosage and Administration Information

The official protocol for Amlodipine Mylan establishes its use as a continuous, once-daily oral therapy, intended as long-term maintenance treatment for chronic cardiovascular conditions. The medication is supplied in tablet form and is strictly administered by the oral route.


Administration Scope and Dosage

The standard starting dose for adult patients managing hypertension or stable angina is 5 mg taken once daily. The dose may be adjusted to a maintenance range of 5 mg up to the maximum daily dose of 10 mg. Dose titration is typically performed slowly, requiring at least 7 to 14 days between adjustments to allow for the stabilization of drug concentrations in the body.

Frequency and Timing: Amlodipine is taken once daily at the same time each day to maintain consistent blood levels. The tablet can be administered with or without food, providing flexibility in the daily schedule. If a dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose; in this circumstance, the missed dose must be skipped, and the patient must not take a double dose.


Population-Specific Dosing Rules

Specific initial dosing instructions apply to certain patient groups. Older adults and those with hepatic impairment are commonly started on a lower initial dose of 2.5 mg once daily as a procedural precaution. For pediatric patients (ages 6–17) with hypertension, the labeled starting dose is 2.5 mg once daily, with a defined maximum dose of 5 mg once daily. No initial dose adjustment is required for patients with renal impairment.

Advertisements

Recent Clinical Evidence

Amlodipine Mylan: Recent Clinical Evidence

Mechanism of Action and Therapeutic Use

Amlodipine, the active substance in Amlodipine Mylan, is a dihydropyridine calcium channel blocker. Clinical evidence consistently supports its primary mechanism, which involves inhibiting the influx of calcium ions across the membranes of vascular smooth muscle and cardiac muscle. This inhibition results in the vasodilation of peripheral arterioles and coronary arteries, leading to a reduction in peripheral vascular resistance.

This pharmacological action has been extensively studied in the treatment of hypertension (high blood pressure) and chronic stable angina pectoris (chest pain).


Key Clinical Findings Overview

Large-scale clinical trials have investigated the efficacy and safety profile of amlodipine. Findings indicate that its sustained reduction in blood pressure is maintained over the 24-hour dosing interval, supporting once-daily administration. Long-term studies have shown that blood pressure control achieved with amlodipine is associated with a reduction in cardiovascular events, though these outcomes depend on individual patient characteristics and risk factors.

Research has specifically focused on its use in vulnerable populations, including patients with coronary artery disease (CAD) and chronic heart failure (CHF) without worsening the underlying condition, which is a key consideration for this class of medication.


Tolerability and Safety Profile

The most frequently reported adverse events are generally dose-related and consistent across the amlodipine formulation. Common reported side effects in trials include peripheral edema (swelling of ankles/feet), headache, and fatigue. These events are typically mild-to-moderate and often diminish with continued use, though patients are advised to consult a healthcare provider regarding persistent symptoms. Studies support that amlodipine is generally well-tolerated by the majority of patients when administered within approved dosage ranges for its indicated uses.

Key Studies & References Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Amlodipine Mylan (FAQ)


Q: How quickly does Amlodipine Mylan start to work after the first dose?

Amlodipine Mylan is a medicine intended for long-term use. Official drug information describes the onset of action as gradual, noting that nearly the full therapeutic effect on blood pressure is typically observed within two weeks (14 days) of beginning regular treatment.


Q: Is it normal to feel tired in the first week of taking Amlodipine Mylan?

Regulatory documents list fatigue and somnolence (sleepiness) as common side effects of this medicine. Safety notes indicate that effects like somnolence may be more noticeable at the beginning of treatment. These events are often described as mild-to-moderate and may diminish with continued use.


Q: Can Amlodipine Mylan affect sleep or cause insomnia?

Insomnia, which is difficulty sleeping, is listed in regulatory documentation as an uncommon side effect of Amlodipine. Conversely, somnolence, or sleepiness, is reported as a common side effect.


Q: What types of over-the-counter pain relievers might interact with Amlodipine Mylan?

Some authoritative sources note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may make Amlodipine less effective at lowering blood pressure, particularly with long-term, regular use. Specific studies cited in drug interaction documents indicate that antacids containing magnesium and aluminum hydroxide do not significantly affect the absorption of Amlodipine. Acetaminophen is not specifically listed as an interacting substance in primary documents.


Q: Can Amlodipine Mylan cause changes in weight?

Official safety data lists both weight gain and weight decrease as less common (uncommon or rare) adverse reactions that have been reported with the use of Amlodipine.


Q: Can Amlodipine Mylan affect kidney function over time?

Regulatory documents state that changes in Amlodipine plasma concentrations are not related to the degree of renal impairment (poor kidney function). Therefore, the need for an initial dose adjustment is not required for patients with renal impairment.


Q: Does long-term use of Amlodipine Mylan change how well it works?

Amlodipine Mylan is a continuous, long-term maintenance treatment. Clinical trials indicate that the intended reduction in blood pressure achieved with Amlodipine is sustained during long-term therapy.


Q: Is Amlodipine Mylan a medicine that is usually taken for life?

Amlodipine is prescribed for chronic conditions like high blood pressure and stable angina. These conditions often require continuous, long-term maintenance therapy for effective management and control, according to regulatory patient information.


Q: What is the research evidence for Amlodipine Mylan in reducing heart events?

In patients with angiographically documented coronary artery disease, Amlodipine is indicated in clinical documents to help reduce the risk of hospitalization due to angina (chest pain). It is also indicated to reduce the risk of needing a coronary revascularization procedure.


Q: Are there any specific safety warnings for women who are pregnant or breastfeeding related to Amlodipine Mylan?

Official drug information states that Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Regulatory documents note that limited human data shows Amlodipine is excreted in breast milk.


Q: Is Amlodipine Mylan suitable for older patients (over 65)?

Amlodipine is used by older adults. Regulatory documentation advises caution because there is potentially reduced drug clearance in this population. Official product information notes that dosage increases for older patients must be handled with caution.


Q: Why is Amlodipine Mylan not recommended for people with very low blood pressure already?

Amlodipine works by lowering blood pressure through vasodilation. Because of this intended effect, caution is advised or use is prohibited in patients with pre-existing conditions such as severe hypotension (very low blood pressure) or cardiogenic shock, as described in official drug information.


Q: What does 'angina pectoris' mean, and how does Amlodipine Mylan help with it?

Angina pectoris is described in patient sources as chest pain or discomfort often caused by not enough oxygen reaching the heart muscle. Amlodipine Mylan helps by relaxing the blood vessels (vasodilation), which increases the supply of blood and oxygen to the heart muscle.


Q: Can Amlodipine Mylan be crushed or split?

Official product information for Amlodipine tablets generally instructs users to swallow the tablets whole and not to cut, crush, or chew them. They are not scored for cutting or splitting unless explicitly indicated on the product packaging.


Q: Does Amlodipine Mylan affect blood sugar levels?

Official drug safety documentation lists hyperglycaemia (an increase in blood sugar) as a very rare adverse reaction reported during the use of Amlodipine.


Q: Can Amlodipine Mylan interact with common allergy medicines?

Amlodipine's metabolism involves the body’s CYP3A4 enzyme system. Regulatory documents identify that strong inhibitors of this enzyme could potentially increase Amlodipine exposure, which may include certain allergy medicines.


Q: How does the medicine Amlodipine Mylan make the heart's work easier?

Amlodipine works by relaxing the walls of the main arteries in the body. This action leads to a reduction in the overall resistance against blood flow, which in turn reduces the demand and workload on the heart’s pumping function.


Q: Is it a common concern that Amlodipine Mylan can cause gum swelling?

Gingival hyperplasia, or gum swelling, is a known adverse effect of this class of medication. However, regulatory documentation lists this as a very rare reaction, meaning it is expected to affect fewer than 1 in 10,000 patients.


Q: Do children ever take Amlodipine Mylan for blood pressure?

Yes, Amlodipine is approved for the treatment of high blood pressure (hypertension) in pediatric patients who are 6 to 17 years old, with specific dosing guidelines for this population described in official documents.


Q: Is it common to experience dizziness or lightheadedness when starting Amlodipine Mylan?

Dizziness is listed as a common side effect of Amlodipine. Official safety information notes that effects like dizziness may be more noticeable particularly at the start of treatment due to initial blood pressure changes.


Q: Can Amlodipine Mylan be taken at any time of day?

Regulatory guidelines state that Amlodipine should be taken once daily. While it can be taken at any time of day, it must be taken at approximately the same time every day to maintain a consistent drug level in the blood.


Q: Is it OK to drink alcohol in moderation while taking Amlodipine Mylan?

Regulatory documentation notes that alcohol may cause an additive effect of lowering blood pressure when taken with Amlodipine. This combined effect may result in symptoms such as dizziness or lightheadedness.


Q: Is Amlodipine Mylan known to interact with stomach acid blockers or antacids?

Official drug interaction studies indicate that an antacid containing magnesium and aluminum hydroxide does not significantly affect the absorption of Amlodipine into the body.


Q: Are there any known severe allergic reactions associated with Amlodipine Mylan?

Yes, severe allergic reactions are documented as very rare adverse reactions in official drug safety information. These include angioedema (swelling of the face, lips, or tongue) and severe skin reactions such as Stevens-Johnson Syndrome.


Q: Do any official drug sources mention Amlodipine Mylan affecting mood?

Yes, mood changes are mentioned in official regulatory documents. Anxiety and depression are listed as uncommon adverse effects, and confusion is listed as a rare effect.


Q: Is Amlodipine Mylan considered safe for people with heart failure?

Clinical studies have specifically examined Amlodipine’s use in patients with chronic heart failure (CHF). Findings indicate that it does not typically worsen the underlying heart condition, which is an important consideration for this class of medication.


Q: Why is the medicine sometimes taken in the morning and sometimes at night?

Regulatory guidance specifies that Amlodipine should be taken once daily. The specific time of day (morning or night) is flexible based on the patient's schedule, provided the tablet is taken at approximately the same consistent time every day to ensure continuous blood levels.


Q: Is Amlodipine Mylan related to the medicine nifedipine?

Amlodipine belongs to a specific chemical group of medicines known as dihydropyridine derivatives. Official documents advise caution in patients with known hypersensitivity to Amlodipine or other medicines within this derivative class, which includes nifedipine.


Q: Do official patient information leaflets mention Amlodipine Mylan affecting vision?

Yes, visual disturbance is listed in regulatory documentation as an uncommon side effect. This can include effects such as double vision (diplopia).


Q: What should be avoided when taking Amlodipine Mylan?

Official drug documents advise avoiding grapefruit or grapefruit juice, as this can increase Amlodipine levels in the blood. Co-administration with Dantrolene infusion must also be avoided. Caution is advised regarding the use of alcohol and certain medicines known as strong CYP3A4 inhibitors or inducers.


Q: Is it true that blood pressure medicines like Amlodipine Mylan take a few weeks to reach their full effect?

Regulatory guidance notes that almost all of the intended blood pressure lowering effect is apparent within two weeks (14 days) of starting treatment. For this reason, official guidance suggests that dose adjustments are typically not made more frequently than every 7 to 14 days.

Advertisements

How should Amlodipine Mylan be stored and disposed of?

Official Storage and Disposal Requirements

Labeled Storage Temperature Requirements: Store at controlled room temperature, typically below 25 C or 30 C, and avoid excess heat.
Light/Moisture Protection Requirements: Must be protected from light and moisture (or humidity).
Packaging-Related Storage Rules: Keep the tablets in the original container and ensure the container is tightly closed to maintain protection.
Child-Protection Storage Requirements: Medication must be stored out of the sight and reach of children.
Disposal Instructions (as documented in government sources): Dispose of unused or expired product according to local requirements. Utilize an approved drug take-back program where available, or follow household trash disposal rules by mixing the medication with an undesirable substance (e.g., dirt, coffee grounds) and placing it in a sealed container, ensuring the package label's personal information is obscured.

Official regulatory documents define the storage environment by mandating a temperature constraint and demanding that the product be protected from light and moisture. This ensures the tablets maintain stability up to the expiration date. Furthermore, the label explicitly requires the product be kept away from children. Disposal instructions guide users to an appropriate method—either a drug take-back program or secure household trash disposal—to prevent environmental release and misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlodipine Mylan found in:

A-Z Index: